checkAd

    Kaival Brands Innovations Group, Inc. (OTCQB  142  0 Kommentare KAVL) Acquires U.S. Patent and International Patent Applications to Produce Nicotine Cessation Products - Seite 2

    “Billions of smokers and tobacco users worldwide are looking for an answer and real solution to their nicotine addiction problems. Imagine patent-protected products, either approved pharmaceutically or made available over-the-counter, that offer a way to truly ease a user off their addictive cravings for nicotine without losing any of their accustomed benefits along the way. We are excited to develop these innovative patents and bring effective, enjoyable smoking cessation products to an expanding market, helping all nicotine users lead healthier and higher-quality lives,” expressed Patel.

    According to a Global Smoking Cessation Market Analysis 2019, the smoking cessation market is projected to reach $63.99 billion by 2026, growing at a CAGR of 16.9% during 2018 to 2026. The study defines smoking cessation as the process of discontinuing tobacco smoking and includes products such as chewing gum, inhalers, lozenges, patches, sprays, and sublingual tablets and therapies such as nicotine replacement therapy (NRT), non-NRT therapy and e-cigarettes.

    Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) is a fast-growing company focused on generating wealth by seeking to incubate innovative products into mature and dominant brands in their respective markets. Our vision is to develop internally, acquire or own, and exclusively distribute these profitable brands with recognizable innovation and superior quality. Learn more now at www.kaivalbrands.com.

    Kaival Labs, Inc., the latest addition to Kaival Brands Innovations Group, Inc., is a wholly-owned subsidiary. Kaival Brands believes Kaival Labs will pioneer the movement in creating a future that is free from nicotine addiction, become an additional advocate with Kaival Brands against underage smoking, and will play an essential role in transitioning millions of smokers worldwide to a tobacco-free life. To learn more about Kaival Labs, its advocacies, and how isomer-specific synthetic nicotine can help curb nicotine addiction, visit www.kaivallabs.com.

    - - - - -

    Forward-Looking Statements

    This press release includes statements that constitute “forward-looking statements” within the meaning of federal securities laws, which are statements other than historical facts that frequently use words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “position,” “should,” “strategy,” “target,” “will” and similar words.  All forward-looking statements speak only as of the date of this press release. Although we believe that the plans, intentions, and expectations reflected in or suggested by the forward-looking statements are reasonable, there is no assurance that these plans, intentions, or expectations will be achieved. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecasted in such statements.  

    Seite 2 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Kaival Brands Innovations Group, Inc. (OTCQB KAVL) Acquires U.S. Patent and International Patent Applications to Produce Nicotine Cessation Products - Seite 2 GRANT, FL, Sept. 28, 2020 (GLOBE NEWSWIRE) - via NetworkWire – Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) (“Kaival Brands,” the “Company,” or “we”), a company focused on growing and incubating innovative and profitable products into …